Crizotinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Crizotinib: From ALK-Positive Non-Small Cell Lung Cancer to Lung Germ Cell Tumor
One-Sentence Summary
Crizotinib is a first-generation, oral ATP-competitive inhibitor of ALK, ROS1, and MET receptor tyrosine kinases, originally approved for treatment of ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC). The TxGNN model predicts it may also be applicable to Lung Germ Cell Tumor (rank 7 of 10 predicted indications; prediction score 99.73%), based on the hypothesis that ALK rearrangements or MET amplification — known oncogenic drivers across diverse tumor types — may occasionally occur in this rare histology. Currently 4 clinical trials (primarily broad ALK-positive basket studies) and 20 publications provide indirect mechanistic and clinical context supporting this prediction, which carries the highest actionability level (S2, Proceed with Guardrails) among all predictions in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive or ROS1-positive advanced non-small cell lung cancer |
| Predicted New Indication | Lung Germ Cell Tumor |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L3 |
| US Market Status | ✗ Not Marketed (per evidence pack; NDA data likely requires re-query — Xalkori® is commercially available) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known published information, Crizotinib (Xalkori®) is a small-molecule inhibitor that competitively blocks ATP binding at the kinase domains of ALK, ROS1, and c-MET receptor tyrosine kinases, thereby suppressing downstream proliferative and survival signaling cascades (including RAS-MAPK and PI3K-AKT pathways). Its efficacy in EML4-ALK rearranged and ROS1 fusion-positive NSCLC has been robustly established in Phase 3 trials, with FDA approval granted in 2011 (ALK-positive NSCLC) and 2016 (ROS1-positive NSCLC).
Primary lung germ cell tumors are exceedingly rare, and their molecular landscape is not well-characterized. However, ALK rearrangements have been described across a broader spectrum of lung neoplasms beyond classical adenocarcinoma — including inflammatory myofibroblastic tumor (IMT), large-cell neuroendocrine carcinoma (PMID 32651063), and atypical carcinoid — with documented crizotinib sensitivity in ALK-positive cases. The TxGNN graph neural network likely captures structural proximity in the disease knowledge graph between lung germ cell tumors and other ALK-driven lung malignancies, generating this prediction through topological inference rather than direct disease-specific evidence.
The mechanistic rationale is plausible but contingent on biomarker confirmation. A biomarker-unselected lung germ cell tumor would have no biological basis for crizotinib sensitivity; however, a case confirmed to harbor ALK rearrangement or MET amplification by next-generation sequencing would carry a clear therapeutic hypothesis. The MATCH platform trial (NCT02465060) provides the most appropriate existing clinical framework to evaluate such a hypothesis prospectively across rare histologies.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02465060 | Phase 2 | Active, Not Recruiting | 6,452 | NCI-MATCH molecular platform: assigns patients with refractory solid tumors to targeted therapy arms based on genomic profiling; ALK inhibitor sub-trial may capture rare ALK-positive tumors including germ cell histologies — largest available molecular-matching framework |
| NCT01121588 | Phase 1B | Terminated | 44 | Crizotinib in non-NSCLC ALK-positive solid tumors; basket design enrolling diverse ALK+ histologies; terminated but with 44 enrolled patients providing indirect safety and activity signal for rare ALK-driven tumors |
| NCT02223819 | Phase 2 | Completed | 34 | Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy; demonstrates tolerability of crizotinib as adjuvant strategy in a non-NSCLC solid tumor (indirect, MET-pathway rationale) |
| NCT02568267 | Phase 2 | Active, Not Recruiting | 534 | STARTRK-2: Entrectinib (ALK/ROS1/NTRK inhibitor) basket study in ALK/ROS1 fusion-positive solid tumors; not crizotinib, but validates the cross-histology ALK/ROS1 basket approach and provides comparator context |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37012551 | 2023 | Phase 1 RCT | Nature Medicine | Lorlatinib (3rd-gen ALK inhibitor) with/without chemotherapy in relapsed/refractory ALK-driven neuroblastoma; confirms role of ALK-targeted therapy in pediatric non-NSCLC ALK-positive tumors and highlights limitations of crizotinib (insufficient potency) in this setting |
| 28183697 | 2017 | Phase 1/2 | Cancer Discovery | Entrectinib (ALK/ROS1/NTRK inhibitor) in advanced solid tumors with gene fusions; antitumor activity demonstrated across multiple histologies — provides cross-histology ALK/ROS1 inhibitor rationale |
| 32651063 | 2021 | Case Report | Clinical Lung Cancer | Novel PLB1-ALK rearrangement identified by NGS in lung large-cell neuroendocrine carcinoma with crizotinib sensitivity; most directly relevant case for rare ALK-positive lung histologies beyond NSCLC |
| 31559892 | 2020 | Case Report | Cancer Biology & Therapy | Primary pulmonary atypical carcinoid with EML4-ALK rearrangement; demonstrates ALK-driven neuroendocrine lung neoplasms exist and may be targetable — relevant precedent for rare lung tumor ALK biology |
| 27573755 | 2016 | Review | Annals of Oncology | Comprehensive review of ALK gene alterations across tumor types (point mutations, fusions, amplifications); supports ALK as a pan-histology oncogenic driver and framework for biomarker-driven crizotinib use |
| 22968692 | 2012 | Review | Targeted Oncology | ALK as a therapeutic target in NSCLC, ALCL, and neuroblastoma; establishes cross-histology rationale for crizotinib beyond its original approval |
| 30790327 | 2019 | Observational | Histopathology | ALK expression characterized in treatment-naive small-cell lung cancer; demonstrates ALK status can be present in non-NSCLC lung tumors and supports broad lung tumor biomarker screening |
| 37561984 | 2023 | Review | JCO Precision Oncology | ALK inhibitors in adult-onset neuroblastoma enriched for somatic ALK mutations; highlights response limitations of crizotinib and rationale for next-generation ALK inhibitors in ALK-driven non-lung tumors |
| 28960893 | 2017 | Preclinical | Cancer Medicine | Crizotinib targets ALK, ROS1, and MET in glioblastoma stem cells; demonstrates crizotinib activity in non-NSCLC, non-hematologic malignancies and MET/ALK co-targeting potential |
| 26122839 | 2015 | Translational Review | Cancer Research | Development pathway of crizotinib resistance in neuroblastoma and rationale for next-generation ALK inhibitors; informs realistic expectations for crizotinib efficacy in ALK-positive tumors with point mutations versus fusions |
US Market Information
No FDA license records were retrieved in the current evidence pack (0 NDAs, market status recorded as not marketed). This appears to be a data gap — Crizotinib is commercially available as Xalkori® (Pfizer Inc.) with FDA approval for ALK-positive metastatic NSCLC (2011), ROS1-positive metastatic NSCLC (2016), and ALK-positive pediatric NSCLC (2021). A re-query of FDA’s drug database (Drugs@FDA) is recommended to populate this section with complete NDA records and approved labeling.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — ALK/ROS1/MET tyrosine kinase inhibitor (not conventional cytotoxic chemotherapy) |
| Myelosuppression Risk | Low to Moderate — neutropenia and lymphopenia reported; not the primary dose-limiting toxicity |
| Emetogenicity Classification | Low to Moderate — nausea and vomiting are common (CTCAE Grade 1–2) but rarely dose-limiting |
| Monitoring Items | CBC with differential (neutropenia monitoring), LFTs/ALT/AST/total bilirubin (hepatotoxicity — including risk of fatal fulminant liver failure, PMID 26898609), ECG (QTc prolongation and bradycardia), ophthalmologic assessment (vision disorders in ~60% of patients), chest imaging/respiratory symptoms (interstitial lung disease/pneumonitis) |
| Handling Protection | Standard precautions for oral targeted therapy apply; institutional cytotoxic drug handling protocols recommended given antineoplastic classification |
Safety Considerations
Please refer to the package insert for safety information. Based on published literature, clinically significant toxicities known to require active monitoring include:
- Hepatotoxicity: Fatal fulminant liver failure has been reported (case report PMID 26898609); LFT elevation is common and may require dose interruption
- Cardiotoxicity: Simultaneous QT prolongation, bradycardia, and ventricular arrhythmia have been reported (PMID 29717400); ECG monitoring is essential
- Interstitial Lung Disease / Pneumonitis: Drug-induced organizing pneumonia reported in ROS1-positive NSCLC (PMID 37062732); requires early recognition and corticosteroid management
- Dermatologic reactions: Erythema multiforme reported (PMID 25994067); monitor for skin changes
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Lung germ cell tumor with confirmed ALK rearrangement or MET amplification represents a biologically coherent but extremely rare target population; the MATCH platform trial (NCT02465060) and a prior ALK-positive basket Phase 1B study (NCT01121588) provide the closest available clinical evidence framework, and the cross-histology ALK inhibitor literature establishes a mechanistic basis for biomarker-selected investigation.
To proceed, the following is needed:
- Biomarker profiling: Mandatory ALK FISH/IHC, ROS1 FISH, and MET amplification by NGS on tumor tissue before any crizotinib use — no biomarker confirmation means no treatment rationale
- MOA data retrieval: Query DrugBank API (DB08865) to populate the currently missing mechanism of action data
- Package insert / safety data: Retrieve FDA-approved Xalkori® labeling (currently absent from evidence pack) and complete the safety section before clinical decision-making
- MATCH trial sub-group review: Determine whether ALK-positive germ cell or rare non-NSCLC lung histology patients have been enrolled and what outcomes data are available (NCT02465060 results database)
- Next-generation ALK inhibitor consideration: Given that crizotinib resistance develops within ~12 months in NSCLC and crizotinib has insufficient ALK kinase potency in some tumor contexts (neuroblastoma), alectinib or lorlatinib may be superior options if a case is confirmed ALK-positive — a comparative rationale statement should be prepared
- Compassionate use / expanded access pathway: If a confirmed ALK-positive lung germ cell tumor case is identified, initiate contact with Pfizer for expanded access or identify an active basket trial with available ALK inhibitor slots
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.